02 February: Malignant melanoma and beyond

Tuesday 02 February, 2016
Royal Marsden Hospital, London

1-day course: Malignant Melanoma and Beyond: An introduction to Targeted Treatments and Cancer Immunotherapy

Level: Intermediate

Audience: Ideal for research nurses, clinical nurse specialists, administrative staff, clinical trials coordinators

Description: This is a 1-day course describing the recent advances made in targeted treatments for cancer, using malignant melanoma as the primary example. Delegates will learn about the faulty genes, pathways and proteins that drive malignant melanoma and other solid tumours, and the mechanism of action of targeted treatments such as B-Raf inhibitors and MEK inhibitors. The day also includes an overview of immunotherapy approaches for cancer, including T cell-based treatments and checkpoint inhibitors.

To book, contact: conferenceteam@rmh.nhs.uk  or call: 020 7808 2922


Cancer Cell biology and genetics: key concepts
  • Cells, DNA, chromosomes, genes, proteins
  • Cell division & the cell cycle
  • Causes, types and consequences of DNA damage
  • Drivers of treatment resistance: the cancer microenvironment, genomic instability, intra-tumoural heterogeneity
The cellular and molecular makeup of malignant melanoma (and other solid tumours)
  • How  solid tumours develop
  • Faulty genes and proteins that drive solid tumours
  • Gene mutations in malignant melanoma – the importance of BRAF
  • How cancers hide from and use the immune system
  • How and why cancers spread
Introduction to targeted cancer treatments
  • An overview of current targeted cancer treatments
  • The EGFR/Ras/Raf/MEK/ERK pathway as a drug target
  • Introduction to the science behind monoclonal antibodies and kinase inhibitors
BRAF and MEK inhibitors for malignant melanoma
  • B-Raf inhibitors e.g. vemurafenib & dabrafenib
  • MEK inhibitors e.g. trametinib, cobimetinib, selumetinib
  • Combining B-Raf and MEK inhibitors – why is it better?
  • Blocking signalling pathways in other cancer types – where have we got to?
Immunotherapy for malignant melanoma
  • Cell-based treatments
  • Antigen and DNA vaccines
  • Checkpoint inhibitors e.g. ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab
  • Immunotherapy in other cancer types